Scholar Rock Holding Co. (NASDAQ:SRRK) Director Katie Peng Sells 1,006 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK) Director Katie Peng sold 1,006 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the sale, the director now directly owns 30,319 shares of the company’s stock, valued at approximately $1,043,579.98. This represents a 3.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK opened at $33.97 on Thursday. The company has a market cap of $3.22 billion, a PE ratio of -14.46 and a beta of 0.59. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98. The stock has a 50 day simple moving average of $39.03 and a 200-day simple moving average of $31.86.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SRRK. Wedbush reissued an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Monday. Truist Financial upped their target price on Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Finally, HC Wainwright upped their target price on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $40.86.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors have recently added to or reduced their stakes in SRRK. Intech Investment Management LLC acquired a new stake in Scholar Rock in the third quarter worth approximately $202,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Scholar Rock by 9.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company’s stock valued at $4,027,000 after buying an additional 42,139 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of Scholar Rock by 593.6% in the third quarter. Fisher Asset Management LLC now owns 734,019 shares of the company’s stock valued at $5,879,000 after buying an additional 628,186 shares in the last quarter. FMR LLC increased its holdings in shares of Scholar Rock by 3.1% in the third quarter. FMR LLC now owns 10,196,046 shares of the company’s stock valued at $81,670,000 after buying an additional 308,813 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Scholar Rock by 900.6% in the third quarter. BNP Paribas Financial Markets now owns 36,331 shares of the company’s stock valued at $291,000 after buying an additional 32,700 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.